• Dexcom's CONNECT randomized trial results were published in The New England Journal of Medicine, supporting earlier continuous glucose monitoring in Type 2 diabetes.
• G7 significantly improved glucose control versus routine care in adults not using insulin, with benefits extending to participants taking GLP-1 therapies.
• Findings were first presented at the American Diabetes Association's 2026 Scientific Sessions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610141710BIZWIRE_USPR_____20261014_BW236618) on October 14, 2026, and is solely responsible for the information contained therein.